{"id":"W2947681783","doi":"10.1002/ejhf.1532","title":"Sacubitril/Valsartan Eligibility and Outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: Bridging Between European Medicines Agency/Food and Drug Administration Label, the PARADIGM-HF Trial, ESC Guidelines, and Real World","year":2019,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Care Foundation","funders":"Servier; Boston Scientific Corporation; Daiichi Sankyo Europe; ResMed; Edwards Lifesciences; European Society of Cardiology; Sanofi; AstraZeneca; Bayer; Boehringer Ingelheim","keywords":"Medicine; Sacubitril; Heart failure; Sacubitril, Valsartan; Valsartan; Ejection fraction; Enalapril; Guideline; Internal medicine; Cardiology; Intensive care medicine; Blood pressure; Angiotensin-converting enzyme","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006324463,0.0004507091,0.001075043,0.0002576508,0.0002700332,0.0002582682,0.0002634828,0.00004806228,0.00002966134],"category_scores_gemma":[0.0003356129,0.0002523207,0.0001566584,0.0003327427,0.0002521981,0.0003108023,0.0001423916,0.0007288332,0.00002032889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004831613,"about_ca_system_score_gemma":0.0001256992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004108114,"about_ca_topic_score_gemma":0.0003399884,"domain_scores_codex":[0.995172,0.001785998,0.001387137,0.0005167461,0.0006979465,0.0004401378],"domain_scores_gemma":[0.9979017,0.0004444667,0.0004861231,0.0007082797,0.000153616,0.000305847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001111542,0.0001867735,0.8729631,0.0001851738,0.0002429119,0.0004308645,0.001133823,0.000001210093,0.0003113325,0.00007603467,0.1205215,0.00283572],"study_design_scores_gemma":[0.01728118,0.002338447,0.8117133,0.0007483879,0.0005501917,0.0006863467,0.0007193673,0.00001038189,0.00006175491,0.00004292188,0.1655425,0.0003052623],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7827952,0.001216646,0.0000235692,0.2143177,0.0001466418,0.001200071,0.00001122691,0.00003062336,0.0002583237],"genre_scores_gemma":[0.9941779,0.0003513953,0.001940908,0.001933821,0.0009476063,0.000004531793,0.00002575373,0.00005959643,0.0005584738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2123839,"threshold_uncertainty_score":0.9999929,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04177887841795871,"score_gpt":0.3317047626631524,"score_spread":0.2899258842451937,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}